Evaluation of 68Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors

Abdominal Imaging

Volumn 40, Issue 2, 2015, Pages 299-309

  Sharma, Punit ^a,b   Arora, Saurabh ^b   Dhull, Varun Singh ^b   Naswa, Niraj ^b   Kumar, Rakesh ^b   Ammini, Ariachery C ^b   Bal, Chandrasekhar ^b  

^a Eastern Diagnostics India Ltd   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

68Ga DOTANOC PET CT; Neuroendocrine tumor; Pancreas; Restaging; Staging

Indexed keywords

GALLIUM; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EVALUATION STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; PANCREAS; PANCREATIC NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; PANCREAS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84925297183     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-014-0219-5     Document Type: Article

References (28)

1. Yao JC, Hassan M, Phan A, et al. (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
2. Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19:753–781
3. Nissen NN, Kim AS, Yu R, et al. (2009) Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am Surg 75:1025–1029
4. Kitajima K, Murakami K, Yamasaki E, et al. (2010) Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol 12:452–459
5. Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto MFH (2002) Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 32:690–694
6. 68Ga-DOTATOC PET and 111 In-DTPAOC (octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626
7. Krausz Y, Rubinstein R, Appelbaum L, et al. (2012) Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med 37:57–62
8. Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19:783–798
9. Zimmer T, Stölzel U, Bäder M, et al. (1996) Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 39:562–568
10. Geijer H, Breimer LH (2013) Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 40:1770–1780
11. Kumar R, Sharma P, Garg P, et al. (2011) Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21:2408–2416
12. 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 40:897–907
13. Zhernosekov KP, Filosofov DV, Baum RP, et al. (2007) Processing of generator-produced 68 Ga for medical application. J Nucl Med 48:1741–1748
14. Al-Ibraheem A, Bundschuh RA, Notni J, et al. (2011) Focal uptake of 68 Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging 38:2005–2013
15. Naswa N, Sharma P, Kumar A, et al. (2011) Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 197:1221–1228
16. Wild D, Christ E, Caplin ME, et al. (2011) Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 52:1073–1078
17. Kumar U, Sasi R, Suresh S, et al. (1999) Subtype-selective expression of the five somatostatin receptors (hSSTR1–5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48:77–85
18. 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 52:886–890
19. Taïeb D, Neumann H, Rubello D, et al. (2012) Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med 53:264–274
20. 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455
21. Naswa N, Sharma P, Gupta SK, et al. (2014) Dual tracer functional imaging of Gastroenteropancreatic Neuroendocrine tumours using 68 Ga-DOTANOC PET-CT and 18F-FDG PET-CT: competitive or Complimentary? Clin Nucl Med 39:e27–e34
22. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458–511
23. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518
24. Versari A, Camellini L, Carlinfante G, et al. (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 35:321–328
25. Baum RP, Kulkarni HR (2012) THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka Experience. Theranostics 2:437–447
26. Koopmans KP, Neels OC, Kema IP, et al. (2008) Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26:1489–1495
27. 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765–770
28. Mayerhoefer ME, Ba-Ssalamah A, Weber M, et al. (2013) Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol 23:1978–1985